To characterize the transplacental effects of @entity2072 on the developing brain, we have developed a @entity19 model of gestational @entity2072 exposure. Pharmacokinetic analysis revealed that @entity2072 and its metabolites (BE, BNE, and NC) were found in fetal brain and plasma at 30 and 120 min following SC administration to embryonic day (E) 17 pregnant Swiss Webster @entity19 . Pregnant dams injected twice daily with @entity2072 @entity5828 at 20 mg/kg SC from gestational day E8 to E17 (COC) demonstrated less food intake and lower percentage @entity1017 than vehicle-injected dams allowed access to food ad lib (SAL). A nutritionally paired control group of dams injected with saline vehicle and pair-fed with the COC dams (SPF) demonstrated the lowest percentage @entity1017 of all three groups. The surrogate fostered offspring of COC and SPF dams demonstrated persistent @entity851 [on postnatal days (P) 1, P9, and P50] and transient @entity851 (on @entity69689 ) when compared to pups born to SAL dams. We conducted behavioral tests that allowed us to dissociate the indirect effect of @entity2072 -induced @entity3147 from a direct effect of prenatal @entity2072 administration in altering postnatal behavior. Pups from all three groups were tested for first-order Pavlovian conditioning on P9 or P12, or for the ability to ignore redundant information in a blocking paradigm on P50 or @entity28349 . Unlike the SPF and SAL controls, COC @entity19 (i.e., @entity19 born to COC dams) were unable to acquire an aversion to an odor previously paired with shock on P9. This @entity4207 was transient because on P12, COC @entity19 trained on the same conditioning task displayed an aversion to the odor that was indistinguishable from the SPF and SAL controls. P50 and @entity28349 COC @entity19 (and to a lesser extent, SPF @entity19 ) demonstrated a persistent behavioral deficit in the blocking paradigm, which may reflect alterations in selective attention. We discuss how these findings in our rodent model have developmental implications for @entity1 @entity1 exposed to @entity2072 in utero.

Transplacental XXXX exposure. 1: A rodent model.

@entity1 :: ('9606', 'Species') :: ['human', 'infants'] @entity851 :: ('MESH:D006130', 'Disease') :: ['growth retardation', 'brain growth retardation'] @entity69689 :: ('22673;20024', 'Gene') :: ['P1 and P9'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity28349 :: ('72119(Tax:10090)', 'Gene') :: ['P100'] @entity2072 :: ('MESH:D003042', 'Chemical') :: ['cocaine'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity5828 :: ('CHEBI:17883', 'Chemical') :: ['HCl'] @entity4207 :: ('MESH:D007859', 'Disease') :: ['learning deficit'] @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']
@entity2072 :: (MESH:D003042,Chemical) :: ['cocaine']
